LMG Life Sciences Recognizes Five Debevoise Partners as 2018 Life Sciences Stars

5 October 2018

LMG Life Sciences, the definitive guide to North American law firms and lawyers focused on the life sciences industry, has named five Debevoise & Plimpton partners 2018 Life Sciences Stars. This year, the Debevoise team of Andrew L. Bab, Mark P. Goodman, Kevin Rinker, Paul D. Rubin and Edwin Schallert were recognized and the team’s recent successes were highlighted in an accompanying editorial analysis compendium.

Each year, LMG Life Sciences selects a distinguished group of legal professionals practicing in the healthcare sector and designates them as Stars. The publication utilizes three key criteria in their evaluation process: case evidence, peer feedback and client feedback.

The Debevoise Healthcare Group addresses transactional, litigation, regulatory and intellectual property matters for leading healthcare companies and for private equity firms investing in the industry. The team – which also includes litigation partner Maura Monaghan and M&A partner Jennifer Chu – provides integrated, cross practice legal advice with efficient and seamless execution covering all aspects of healthcare matters, including corporate and M&A, litigation and compliance, FDA/FTC regulatory, intellectual property, including licensing and collaboration agreements, and cyber security & data privacy. This approach offers clients a “one-stop-shop” for healthcare and life sciences across nearly all subsectors and stages of the industry lifecycle.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. We deliver effective solutions to our clients’ most important legal challenges, applying clear commercial judgment and a distinctively collaborative approach.